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The Annual Report on the State of the Drugs Problem in the
European Union 1997 is important not just for what it says about
drug problems in Europe (summarised in this document), but also
for its revelation of major advances in our ability to make such
statements. Increasingly the nations of Europe speak the same
language on drugs and drug policy  a prerequisite for profiting
from each others experiences and cooperating to safeguard
Europes populations. In this process the EMCDDA can claim a
major role as instigator and midwife. The fruits of these advances
are seen in the enhanced policy relevance of this years report, most
obviously where it branched into new areas:
 A new chapter (chapter 3) on abuse of drugs such as ecstasy
shows how systems and networks have developed to the point where
information can rapidly be disseminated in response to an emerging
concern  and how important this is when drug use itself dissemi-
nates with alarming rapidity.
 Last years discussion of the relation between the EMCDDA and
its international partners is supplemented (in chapter 6) by a practi-
cal demonstration of those relations in action, providing the
perspectives and the data to define Europes place in international
drug trafficking patterns.
 This years analysis of demand reduction activities (chapter 2)
broke new ground through a special study of interventions in
Europes criminal justice systems, giving Member States pointers to
where they can learn from each other in this key sector.
 Last year we admitted that funding was a major gap in our knowl-
edge of national strategies. It remains so, but now the new section in
chapter 4 clearly defines the gap, analyses the issues involved in
filling it, and draws on new data from the EU and elsewhere which
shows the way forward.
 Chapter 1 now documents the worrying extent of hepatitis (espe-
cially hepatitis C) infection among injecting drug users, and data has
improved to the extent that we can present meaningful figures on
problem drug use  key inputs for Europes policymakers and planners.
Other advances will be less apparent but still solidify the platform
for policy making at national and EU level. These are just a few
examples:
 For chapter 1 new surveys have enabled us to cover more drugs
and to document the extent of relatively current drug use in the
general population, a major advance in policy-relevant information.
 An EMCDDA study of the language of demand reduction sharp-
ened the categories in this sector and led (in chapter 2) to a more
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diversified description and analysis of such activities.
 In chapter 4 we see clear evidence of a spiralling process where
increased scope for meaningful debate between EU nations produces
benefits which encourage more of the same. Information from the
EMCDDA (and the Europol Drugs Unit) was commended as par-
ticularly helpful by the Conference on Drugs Policy in Europe held
in 199596 and by the subsequent European summits. Such events
stimulate national developments which in turn improve the informa-
tion available to the EMCDDA.
Last year I said the results presented in our first report justified the
efforts required. That is even more so for this report. Investing
relatively small sums in comparability improvements clearly has the
ability to maximise the targeting, effectiveness and quality of na-
tional anti-drug expenditures. It is also clear that achieving this
benefit demands deepened cooperation between data providers and
those charged with producing EU-level information for policy
makers. At the heart of this system is the EMCDDAs REITOX
network and its focal points in each Member State. Focal points
must have the resources and the freedom to work with their data
providers on the one hand and with the EMCDDA on the other to
create the scope for even more useful analyses. Progress entails
being in a position to adopt common standards for best practice
from wherever these derive, even if this means amending national
data collections systems.
A companion technical report based on this years findings is being
disseminated to Europes leaders, administrators and experts in the
drug information field. As empowered under the EMCDDAs found-
ing regulation, in that report we will make our recommendations
with the force justified by the ultimate aim  to safeguard Europes
people, and especially our children, from the risks of drug misuse.
But there is one very basic objective, to which the coming millen-
nium attaches an obvious time scale: by the year 2000, to have
promoted a survey of the extent and nature of drug use across the
European Union, with each country adopting compatible method-
ologies to enable us to define the scale of the problem with unprec-
edented confidence. The Treaty on European Union created the
necessary framework for taking this decisive step forward. If we
enter the new era without having grasped this opportunity, we will
have failed even to approach the sophistication our people deserve.
I hope you find this summary useful, will be stimulated to obtain the
full report, and will support our work for those affected by drug
problems in Europe.
Georges Estievenart
DIRECTOR, EMCDDA
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5stablished in Lisbon in 1994, the European
Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) is a European Com-
munity information agency charged by its founding
regulation to provide objective, reliable and com-
parable information at European level concerning
drugs and drug addiction and their consequences.
It gathers and disseminates information on:
the demand for drugs and measures to reduce
that demand;
national and European Community strategies and
policies;
international cooperation and the geopolitics of
the supply of drugs;
control of trade in narcotic drugs, psychotropic
substances and precursor chemicals;
implications of the drugs phenomenon for pro-
ducer, consumer and transit countries.
The Centres Annual Report on the State of the Drugs
Problem in the European Union (this publication is
a summary of the 1997 report) is its main informa-
tion dissemination vehicle. Much of the data for the
report derives directly or indirectly from the
EMCDDAs partners in the national focal points of
the 15 Member States and in the European Com-
mission, or from the EMCDDAs six priority interna-
tional partners. The core problem with which the
EMCDDA and its partners grapple is ensuring the
availability and comparability of information from
varied national data collection systems embedded
in divergent cultures and administrative structures.
A simple example is that cannabis arrests in a coun-
E
try which generally deals with cannabis through non-
penal measures may be far fewer than in a country
which strictly enforces its prohibition, yet cannabis
use may be higher.
The ultimate objective is to provide policymakers
and others with an information base from which they
can compare the effectiveness of policies and prac-
tices; as noted in this report and acknowledged in
other EU documents, progress this year has been
clear and decisive. This summary presents essential
background information and highlights from a re-
port of over 140 pages in length. Copies of the full
report are easily available in each Member State 
see back page.
In many countries epidemiological research on
illegal drug use is a developing science and infor-
mation is inadequate. At European level national
differences render data from one nation incompat-
ible with seemingly similar data from another na-
tion. However, converging conclusions from several
sources permit some general observations to be
made.
In many countries there appears to be increasing
use of new drugs such as ecstasy and, in some
countries, crack cocaine, as well as of more familiar
drugs such as powdered cocaine, cannabis and
amphetamines.
In general, only a small minority of people who
have tried a drug have done so recently or repeat-
edly, yet ever used figures are often the only ones
available. Policy responses based on these figures
alone risk over-reaction.
In most EU Member States heroin dominates
indicators which reflect various problematic conse-
quences of drug use, such as the demand for treat-
ment, drug-related deaths and HIV infection. Com-
binations of drugs, including medicines and alcohol,
play a continuing and increasingly important part
in problems associated with illegal drugs.
 Extent of use 
Throughout the European Union cannabis is the
most commonly used illegal drug; depending on the
country, from 58% to 2030% of the population
have at least tried the drug. However, use is
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The reports major contents are listed below.
Chapters 16 are summarised in this boooklet.
Chapter 1 Prevalence and patterns of use
Chapter 2 Demand reduction
Chapter 3 New trends in synthetic drugs
Chapter 4 National strategies
Chapter 5 Action taken by the EU
Chapter 6 The international environment
Annexe 1 The drugs described
Annexe 2 The EMCDDA and REITOX
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6 commonly occasional or intermittent rather than fre-
quent and the drug rarely appears as the primary
drug in health and social care indicators.
European populations usually have less experi-
ence of heroin than of almost any other drug. Typi-
cally under 1% of the general adult population have
ever tried the drug, but among younger adults in
major cities heroin addiction can be much more
prevalent than the national average. Heroin remains
a major threat to public health and public safety.
 Indicators of drug problems 
In most countries opiates (heroin mainly) are re-
ported most often as the primary substances used
by problem drug users; however most of these opi-
ate users also use other drugs, especially cocaine
(polydrug use). Some countries in northern Europe
have significant numbers of amphetamine injectors,
who tend not to use opiates; in a few countries these
form the majority of  problem drug users.
Although there are exceptions, capital cities tend
to have problem use rates higher than those of pro-
vincial cities and also higher than the national rate.
Between EU nations, monitoring methods and
definitions still differ to such an extent that varia-
tions in reported rates of problem drug use are dif-
ficult to attribute to real differences in prevalence.
In almost all countries, heroin is the main drug
(generally 7095%) among clients starting treatment;
the proportion who inject ranges from 14% to
around 90%, generally lower than the figures re-
ported last year. In some countries amphetamines
are also important. In general, cocaine remains rela-
tively rare as the main problem drug.
Treatment clients tend to be aged between their
early 20s and early 30s; 7085% are men.
Injection seems to be less common among
younger drug users and probably also among those
who started drug use most recently. Compared to
existing clients, a higher proportion of new clients
(who tend to be younger) have problems involving
cocaine and/or cannabis and fewer (but still the
majority) have problems with opiates.
Addicted heroin injectors face a risk of death
which may be 20 or 30 times higher than in the
general population of the same age. Other forms of
drug use pose a far lower risk. Many EU countries
witnessed a marked rise in drug-related deaths in
the second half of the 80s and the early 90s. Since
then trends have diverged with continuing increases
in some countries and decreases and/or or stabili-
sation in others.
Sharing contaminated injecting equipment and
sexual contact are the main transmission routes for
HIV and hepatitis. In many countries injectors have
reduced their sharing of injecting equipment. This
and other infection control measures appear to have
impacted on HIV transmission (in most countries,
the prevalence of HIV infection is stable or decreas-
ing ) but not on hepatitis C. Generally, the rate of
new cases of AIDS is decreasing.
Hepatitis C is estimated to be 50 to 100 times
more infectious than HIV and can lead to chronic
hepatitis and extensive liver damage and/or cancer.
More people may have tried cocaine than have
tried heroin, ranging from 1 to 4% of the general
population. Users tend to be socially integrated
young adults who use intermittently, but cocaine also
has more marginalised  adherents; heroin addicts
who also take cocaine have a profile typical of most
heroin addicts.
Crack smoking has been reported in several coun-
tries in groups similar to heroin users and in other
marginalised groups, but it remains a limited
phenomenon.
In most countries amphetamines are the second
most frequently used illegal drug, generally tried by
up to 3% of adults. From the late 80s many coun-
tries reported that amphetamines, ecstasy and in
some cases LSD had become more popular among
young people, linked to a youth culture based
around discotheques and large house parties (more
in chapter 3).
Among young adolescents prevalence of solvent
misuse may be higher than of any other drug apart
from cannabis.
All charts:
B = Belgium, Flemish
speaking regions only;
D = Denmark
FIN = Finland
F = France
D (1st) =W. Germany
D (2nd) = E. Germany.
E = Spain
S = Sweden
UK = United Kingdom
Age ranges and dates
vary between countries.
1. Younger adults
unavailable.
2. ’Hard drugs’.
3. ’Hard drugs’; results
for younger adults from
a different survey than
for all adults and for
other drugs.
4. Amphetamines and
ecstasy.
5. ’Designer drugs’.
LIFETIME PREVALENCE OF DRUG USE IN RECENT NATIONWIDE SURVEYS
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7The potential burden on society is comparable to
that of the recent HIV epidemic.
There may be half a million drug users infected
with hepatitis C in the European Union. Prevalences
of hepatitis C in injecting drug users are substan-
tially higher than for hepatitis B, even in countries
with a low prevalence of hepatitis B and/or HIV in-
fection. The high rates imply that the risk behaviours
which transmit viruses such as HIV are continuing,
if at a lower rate.
Since the 80s all but a few countries have re-
ported increasing numbers of drug offences; in
some, cannabis accounts for the large majority; in
others, it is heroin. Everywhere the proportion of
offences involving cocaine is low. Drug users con-
stitute a significant proportion of the prison popu-
lation in several, probably many, countries.
 Drug availability and supply 
Drug seizures by law enforcement agencies are
thought indirectly to reflect drug supply and avail-
ability and therefore, possibly, drug consumption.
However, the link is complicated because seizures
are also heavily affected by other factors.
The number of ecstasy seizures is increasing in
all countries. In many northern countries these re-
main well below those for amphetamines; in others
the situation is the reverse.
The price and purity of drugs on the illicit mar-
ket is not always reported and available data is of
unknown reliability. In general, retail prices of can-
nabis are stable or slightly increasing, and for heroin
and cocaine are either stable or falling. All other
things being equal, stable or falling prices imply that
supply is not being reduced relative to demand.
C H A P T E R 2 D E M A N D  R E D U C T I O N
Drug demand reduction interventions aim to de-
crease the demand for drugs or reduce the harmful
consequences of drug use at an individual or col-
lective level; they range from work with the very
young to prevent the onset of demand for drugs to
substitution programmes which prescribe drugs to
addicts. Prevention, outreach, treatment, rehabili-
tation and harm reduction are all included.
Major dimensions along which such activities may
be categorised are:
 basic strategy, such as whether the aim is to avoid
the onset of drug demand or to help drug users re-
duce an existing drug demand;
 objectives, eg, abstinence or controlled use;
 target groups, often defined by their degree of
known involvement with drugs;
 type of drug; some programmes aim to affect use
of all licit and illicit substances, others target spe-
cific substances;
 setting; where the intervention takes place.
Health, social, educational and criminal justice
systems, and voluntary organisations, are imple-
menting a broad range of demand reduction activi-
ties, with different approaches according to the
accessibility and lifestyles of the target populations.
At national level responsibility for demand reduc-
tion is commonly placed in ministries of health, the
interior, education, justice, and defence. They dis-
seminate guidelines and methodologies for local im-
plementation, initiate certain activities and help
coordinate local activities. Many EU countries have
new or revised anti-drug policies and have increased
funding for demand reduction.
In all countries vocational and continuing train-
ing in addiction has become more available.
Despite growing demand for evaluations of
demand reduction activities, research is inadequate.
 Prevention 
Previously prevention featured fear arousal, pun-
ishment and prohibition; now the emphasis is less
on dysfunction and deficiency, more on empower-
ment and strengthening.
A major trend is the increasing professionalisa-
tion of prevention workers due to increases in the
amount of specialised training and posts.
Prevention is thought most effective when organ-
ised close to its targets. The overwhelming majority
of demand reduction work is locally based, focused
on units such as the neighbourhood, the family,
schools or local associations.
While potentially effective, sustained and com-
prehensive community programmes are highly de-
manding due to the range of people and organisa-
tions  which must be reached and involved.
School programmes are at the heart of preven-
tion in all EU countries.
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 Help for drug users 
Expansion, diversification and increasing differ-
entiation characterise developments in helping serv-
ices across Europe. Drug services tend to cater more
for individual needs and increasingly cooperate with
health, social and criminal justice systems. In sev-
eral countries, treatment systems are being reorgan-
ised to improve responsiveness to emerging needs.
Community-based outreach services set out to
reach and maintain contact with high-risk groups in
their own settings; many operate a peer-to-peer
approach relying on (ex-) drug users. Low threshold
services help the most deprived addicts with daily
survival, preventing further deterioration.
Harm reduction approaches have expanded due
to fears over HIV infection and public concern about
the growing drug problem; such approaches have
reduced HIV spread in many countries.
Substitution treatment is available in all EU coun-
tries, but to a widely varying degree. In recent years
most countries have expanded methadone treat-
ment. Eventual abstinence is usually the goal but
treatment may be designed to continue indefinitely.
Non-residential programmes aims to improve the
quality of life of substance users and safeguard their
health while if possible motivating them to seek ad-
diction treatment. Residential facilities range from
detoxification to comprehensive therapy pro-
grammes and may also include services for women
or special groups such as very young drug users or
parents with children.
Treatment and rehabilitation programmes gener-
ally attempt to (re)integrate problem drug users into
society (housing, work, etc)  the process of nor-
malisation.
Aftercare to reinsert ex-drug users into social net-
works and employment constitute the last phase of
long-term treatment, offering job training, halfway
housing, family care, etc.
Significantly more drug users may have contact
with the criminal justice system than with treatment
services. Demand reduction interventions in this
system commonly involve criminal justice agencies
referring drug users to health and social services.
C H A P T E R 3 N E W  T R E N D S  I N  S Y N T H E T I C  D R U G S
In some EU countries unprecedented numbers
of increasingly young Europeans have adopted the
use of synthetic drugs such as ecstasy, LSD and am-
phetamines in the context of a mass youth culture
variously described by the terms rave, techno or,
more generically, dance.
The ease with which synthetic drug use tran-
scends national boundaries and the common cul-
tural context of dance music mean that much can
be gained by sharing experiences.
Ecstasy and amphetamines share stimulant effects
while LSDs effects are primarily emotional and per-
ceptual. The effects of all three share an affinity with
the energetic, mind-altering context of all-night,
rave-type dance events.
The numbers who have tried these drugs and the
frequency of their use have increased since the ad-
vent of rave culture in the late 80s but they remain
a small minority; usually well below 10% of all young
people have tried them and regular use is uncom-
mon. Generally fewer people have tried ecstasy than
LSD and amphetamines, but recent ecstasy use often
exceeds that of the other two drugs.
Users are not concentrated among the marginal-
ised or deprived, but are mostly young, employed
or students, and relatively affluent.
Fatalities and less dramatic harm from ampheta-
mines, ecstasy or LSD seem relatively rare. Annual
recorded national death totals for each drug are
often zero and rarely exceed 10. However, the con-
text of some deaths  normal young people
enjoying a night out  heightens their impact, and
problems may be hidden by the inadequacy of the
data or develop if use patterns become chronic.
Adverse physical effects of amphetamines and ec-
stasy are largely related to their stimulant proper-
ties, which can stress the circulatory and other sys-
tems, and to their use during prolonged bouts of
energetic dancing in hot venues, which can lead to
heatstroke. LSDs physical effects are relatively mild.
Lasting neural impairment has yet to be demon-
strated in human beings  though animal experiments
suggest this could arise from ecstasy use.
Stimulant-induced anxiety and paranoia followed
by depression can occur with amphetamines and
ecstasy, and LSD can cause distressing but usually
temporary symptoms similar to psychosis. Though
rarely seen, heavy amphetamine use can cause a
transient drug-induced psychotic episode. Whether
these drugs can cause lasting psychosis is debatable.
Dependent patterns of use are not uncommon
with amphetamines, but usually not in the context
3
A SCENE FROM THE
EARLY DAYS OF THE
RAVE SCENE  THE
YOUTH DANCE CULTURE
NOW CLOSELY
ASSOCIATED WITH NEW
TRENDS IN USE OF
SYNTHETIC DRUGS
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9of use at dance events. Dependence is not a recog-
nised feature of LSD or ecstasy use. Social and health
problems can arise from excessive or particularly ill-
advised use; impaired driving has received increas-
ing attention. Criminalisation of otherwise socially
integrated youngsters is also a concern.
A wide range of localities, municipalities and na-
tional bodies have recognised the importance of
harm reduction strategies. These have usually been
instigated by non-governmental bodies rather than
by official drug services. Often they seek to persuade
club owners and event organisers to provide safety
features such as improved ventilation, drinking water
and first aid. Increasingly clubs are taking on these
responsibilities.
 T H E
U L T I M A T E
A I M  . . .
TO SAFEGUARD EUROPES
PEOPLE, ESPECIALLY OUR
CHILDREN, FROM THE
RISKS OF DRUG
M I S U S E . 
Georges Estievenart
Prevention tactics often involve adopting the lan-
guage and images of rave culture and using this cul-
ture as a means to promote drug-free events or safer
drug use. Peer education and projects initiated from
within the dance scene are important contributors.
The widespread but illegal nature of drug use at
many dance events means authorities oscillate be-
tween repression and the pragmatic view that on
occasions this might cause more harm than good,
eg, by encouraging illegal events at remote venues.
Synthetic drug use is poorly understood com-
pared to opiate use or the problems of drug injec-
tion. There is a need for studies both of patterns of
use and of the consequences, including those which
follow up users to monitor possible harmful effects.
C H A P T E R 4  N A T I O N A L  S T R A T E G I E S
National drug policies emerged in EU Member
States as drug use increased, demanding a nation-
ally coordinated interdepartmental response. Key
tasks are to balance supply and demand reduction
and to achieve coordination across national bodies
and between national and more local levels.
The major provisions of national laws are increas-
ingly confined by supranational policies deriving
from the UN and the European Community; differ-
ences relate mainly to the severity of punishments,
how major provisions are implemented, and
enforcement practices.
European nations generally recognise addiction
as an illness but the extent to which this perception
pervades penal policy and practice differs.
Although coordination structures and drug laws
changed little in 1996, analysis reveals some impor-
tant policy trends. Radical change is not on the
mainstream political agenda, but in most European
Union countries drug policies are under review in
response to:
 EU-level analyses of drug policy divergences and
convergences between Member States;
 participation of a wider range of people and view-
points due to decentralisation and increasing com-
munity involvement;
 increasingly sound and comparable information
enabling a degree of scientific evaluation of policies,
in turn encouraging a less ideological and more prag-
matic perspective.
New decentralising measures place a premium
on coordination; where this fails to keep pace, intra-
national policy divergence is apparent.
Despite its policy importance, no EU nation can
claim a comprehensive and reliable accounting of
its anti-drug expenditures or the costs imposed by
drug misuse. Core problems are defining bounda-
ries and accounting for sub-
national expenditure.
A relatively small drug budget
does not necessarily mean less, or
less effective, social action against
drug problems. For example, a
more relaxed (and less expensive)
legal approach can foster social
action, and some anti-drug meas-
ures can aggravate problems
arising from the drug use that they
fail to prevent.
Because it is more centralised,
spending on supply reduction is
more easily accounted for, so
may seem larger relative to de-
mand reduction than is actually
the case.
Though it may seem attractive
to move resources between de-
mand and supply reduction, in
practice, when resources on both sides are
stretched, required increases are made by raising the
global budget or reallocating within sectors.
A critical issue in assessing the costs imposed on
society by drug use is placing a monetary value on
human life. However, such an accounting is needed
to gain a perspective on the appropriate level and
mix of investments devoted to curbing these costs.
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Joint European action against drugs dates back at
least to 1972 and accelerated in the 90s when the
European Council adopted three European Action
Plans on drugs, the last strengthened by the in-
creased scope for cooperation within the Treaty on
European Union.
In 1996 the high profile of the drugs problem was
confirmed when both European Council meetings
addressed the issue in depth, underlining the im-
portance of an integrated approach.
Within a stable institutional, organisational, legal
and political framework, EU action progressed rap-
idly, especially in the second half of 1996 with the
adoption of nine joint actions or common positions
and five resolutions relating to home affairs and
justice cooperation. The co-decision procedure
between Parliament and the Council of Ministers
produced three important public health decisions,
including the Community Action Programme on the
Prevention of Drug Dependence, supported by a
budget of 27m ECUs over five years.
Anti-money laundering measures continued to be
seen as crucial. Progress was made on implement-
ing the anti-laundering directive and Parliament
called for the legislation to be extended.
Available information was greatly enhanced when
the EMCDDA and the Europol Drugs Unit both
produced their first annual reports. Information
agencies were increasingly called upon to provide
the European Council and Parliament with reliable
information on aspects of the problem.
Action in 1996 was marked by an increasing con-
cern with synthetic drugs and with mechanisms to
enable rapid updating of information about their
spread, the resulting problems and responses to
these problems.
In 1996 the global spend on action against drugs
more than doubled to over 61m ECUs. Nearly all
budget lines at least maintained last years levels and
most increased.
Where last years funding was evenly split be-
tween internal and external programmes, in 1996
75% was allocated for external action, representing
a tripling of the external budget. There was a deci-
sive increase in internal funding for monitoring and
demand reduction.
Helping Latin American countries eradicate illicit
drug production and trafficking is a foreign policy
priority for the EU. In 1996 political dialogue with
the region was enriched and a new budget line
allocated 30m ECUs to Bolivia for crop eradication
and substitution programmes.
C H A P T E R 6 T H E  I N T E R N A T I O N A L  E N V I R O N M E N T
Since the beginning of this century nations have
set up international instruments binding them to
adapt their own national policies and laws relating
to drug misuse in order to create a common legal
approach, combating an international phenomenon
with international measures.
The current international legal framework mainly
derives from three major United Nations drug con-
trol treaties: the Single Convention on Narcotic
Drugs of 1961 (amended in 1972); the Convention
on Psychotropic Substances of 1971; and the Con-
vention against Illicit Traffic in Narcotic Drugs and
Psychotropic Substances of 1988.
The core objective of the first two of these treaties
was to confine use of listed drugs to approved medi-
cal and scientific purposes. The third sought to
strengthen international cooperation to combat illicit
trafficking. All 15 EU nations have ratified the first
two of the conventions and all plus the European
Community itself have at least signed the third.
The need for international cooperation in infor-
mation provision was recognised by the European
Community when it stipulated six priority interna-
tional partners for the EMCDDA: the United Nations
International Drug Control Programme (UNDCP);
the World Health Organisation (WHO); the Inter-
national Criminal Police Organisation (ICPO or In-
terpol); the European Police Office (Europol); the
Pompidou Group of the Council of Europe; and the
World Customs Organisation (WCO). A synthesis of
their latest reports provides a perspective on
Europes position in global illegal drug markets.
EU Members States are primarily recipients of
drugs. However, most are also transit countries,
some are now significant producers of synthetic
drugs, and a few act as secondary distribution points.
Highly developed international trade and trans-
portation systems combined with geographical,
5
6
U N D C P
U n i t e d N a t i o n s
International  Drug
Control  Programme
ACROSS THE
TOP OF THE PAGE,
THE SYMBOLS (EXCEPT
UNDCP) OF THE
EMCDDAS SIX
PRIORITY
INTERNATIONAL
PARTNERS
A n n u a l  R e p o r t  o n  t h e  S t a t e  o f  t h e  D r u g s  P r o b l e m  i n  t h e  E u r o p e a n  U n i o n    1 9 9 7
SUM
M
ARY & HIGHLIGHTS
1 1cultural, historic and economic factors affect the role
of individual Member States as entry points and tran-
sit routes. Large seaports in Germany, the Nether-
lands, the UK and Belgium make these countries
vulnerable to the smuggling of major consignments
in legitimate container-transported freight. Linguis-
tic and historic ties influence the role of Spain and
Portugal as entry points for South American cocaine.
The vast majority of heroin seized in the EU origi-
nates from South West Asia before being transported
mainly by lorries starting in Turkey and traversing
neighbouring Balkan states. The creation of depots
in Central and Eastern European countries has led
to a shift to a two-stage smuggling pattern with lor-
ries transferring their loads to private cars at these
depots for delivery mainly to Turkish networks in EU
Member States.
The proliferation of road frontier crossing points,
diversification of trafficking gangs and networks, the
use of air transport and the increasing involvement
of traffickers and couriers of different nationalities
make enforcement increasingly difficult.
The European Union remains in 1996 a major
market for cocaine, second only to the United States.
Morocco and Colombia remain the main providers
of cannabis derivatives for the EU markets, the first
of resin (hashish), the second of herbal cannabis
(marijuana). Indoor cultivation within the EU is now
important in European cannabis markets.
The European Union has become one of the
worlds major illicit production regions for ampheta-
mine and ecstasy-type stimulants. Increasingly these
and other synthetic drugs are being exported by
Central and Eastern Europe and the Baltic States.
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This publication is a highly condensed summary of the Annual Report on the State of the Drugs Problem
in the European Union 1997 from the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA). The full report also includes annexes covering:
the effects and risks of the major drugs or drug groups misused in Europe;
the role and structure of the EMCDDA and partners in the REITOX network linking national focal
points in each Member State and in the European Commission;
contact details for the EMCDDA Management Board and the EMCDDAs international partners.
To obtain a copy of the report contact the EMCDDA via e-mail at info@emcdda.org or contact the
EMCDDA or your national focal point at the following addresses:
EMCDDA
Rua da Cruz de Santa
Apolónia
N” 23/25
1100 Lisboa
Portugal
Tel 351 (1) 811 3000
Fax 351 (1) 813 1711
AUSTRIA
EMCDDA Focal Point
Austrian Federal Institute
for Public Health
Stubenring 6
A1010 Vienna
Tel 43 (1) 515 61 60
Fax 43 (1) 513 84 72
BELGIUM
EMCDDA Focal Point
Scientific Institute of
Public Health Louis
Pasteur
Rue Juliette Wytsman 14
B1050 Brussels
Tel 32 (2) 642 50 24
Fax 32 (2) 642 50 01
DENMARK
EMCDDA Focal Point
National Board of Health
Amaliegade 13 Postbox
2020
DK1012 Copenhagen
Tel 45 (33) 911 601
Fax 45 (33) 931 636
FINLAND
EMCDDA Focal Point
National Research & Devpt.
Centre for Welfare & Health
PO Box 220
Siltasaarenkatu 18 C (3rd
floor)
SF00531 Helsinki
Tel 358 (9) 3967 2378
Fax 358 (9) 3967 2324
FRANCE
French Observatory for
Drugs and Drug Addiction
105 rue Lafayette
F75110 Paris
Tel 33 (1) 53 20 16 16
Fax 33 (1) 53 20 16 00
GERMANY
EMCDDA Focal Point
Institute for Therapy
Research
Parzivalstraße 25
D80804 Münich
Tel 49 (89) 36 08 04 60
Fax 49 (89) 36 08 04 69
GREECE
EMCDDA Focal Point
University Mental Health
Research Institute
74 Vassilisis Sophias Avenue
EL11528 Athens
Tel 30 (1) 722 51 09
Fax 30 (1) 723 36 90
IRELAND
EMCDDA Focal Point
Health Research Board
73 Lower Baggot Street
IRDublin 2
Tel 353 (1) 67 61 176
Fax 353 (1) 66 11 856
ITALY
Permanent Observatory on
the Drug Phenomenon
Ministry of the Interior
via Cavour 6
I00184 Rome
Tel 39 (6) 488 2655/465
39827
Fax 39 (6) 465 39964
LUXEMBOURG
EMCDDA Focal Point
Department for Socio-
therapeutic Action
Ministry of Health
1 rue du PlØbiscite
L2341 Luxembourg
Tel (352) 40 47 40
Fax (352) 40 47 05
The NETHERLANDS
EMCDDA Focal Point
Trimbos Institute
Da Costakade 45
PO Box 725
NL3500 AS Utrecht
Tel 31 (30) 297 11 25
Fax 31 (30) 297 11 28
PORTUGAL
Observatory VIDA
Av Columbano Bordalo
Pinheiro 872°
PT1000 Lisbon
Tel 351 (1) 721 02 70
Fax 351 (1) 727 38 03
SPAIN
EMCDDA Focal Point
Government Delegation
to the National Plan on
Drugs
c/ Recoletos 22
E28001 Madrid
Tel 34 (1) 537 27 25
Fax 34 (1) 537 27 08
SWEDEN
EMCDDA Focal Point
National Institute of
Public Health
S103 52 Stockholm
Tel 46 (8) 5661 35 00
Fax 46 (8) 5661 35 05
UNITED KINGDOM
EMCDDA Focal Point
Institute for the Study of
Drug Dependence
Waterbridge House
3236 Loman Street
Southwark
UKLondon SE1 OEE
Tel 44 (171) 928 1211
Fax 44 (171) 928 1771
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